(TheNewswire)
VANCOUVER, BC – TheNewswire- August 10, 2022 - AREV LIFE SCIENCES GLOBALCORP. (CSE:AREV) (CNSX:AREV.CN) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporationannounces a corporate update on progress of its business streams.
Arev, like many other companies, has felt the impact ofthe lock downs and changes in market conditions as a result ofCovid-19, the war in Ukraine and now global inflation. We believe AREVis very well positioned to make a positive impact in the ClinicalNutrition Sector and in the area of Therapeutic Interventions.
AREV produces ingredients and formulates proprietarytherapeutic interventions with plans to deliver innovation in clinicalnutrition, proprietary supplements, topicals and rational drug design,based on science. The Company’s business model leverages its corecompetency of extraction to produce unique ingredients and compoundsfor its pipeline of products. The Company continues in the productdevelopment and pre-commercialization stage with an expectation thatit will begin commercial sales in 2023.
“ We noticed our messaging wasnot being understood so in an effort to clarify the activities of thecompany we have created business streams that give us flexibility forthe future.”, stated Mike Withrow CEO of AREV.He went on to say, “ We get a lot done withoutmassive dilution. This move gives us the focus needed for eachbusiness stream of the company and makes it easier for the market tounderstand the synergy between each unit.”
The Company has focused its operations as a fullyintegrated enterprise and is now organized to address three coremarket segments; 1) SpecialtyIngredients with extraction of compounds forconsumption and topical use; 2) Clinical Nutrition with next generation Readyto Use Therapeutic Foods (RUTFs) and 3) Technology throughdevelopment of a commercial platform called Medicine Merchant™ whichsupports the growth and efficiency of the Cannabismarketplace.
1 ) SpecialtyIngredients - Leveraging its core competency inextractions, bulk compounds are fractionated into therapeuticcompounds. Arev’s strategy is focused on novel approaches totherapeutic interventions via nutrition, supplementation, and topicalapplications. The Company is conducting research into compoundsthat have been acknowledged to have unique therapeutic benefits. How such compounds work and in what dosage are questions the Companyseeks to answer through its innovative research.
2) ClinicalNutrition - The company invests in researchrelated to phytomedicinal and biologic discoveries of small moleculeantivirals, anti-inflammatories and cellular regeneration. We nowhave a significant footprint in human nutrition including thedevelopment of a Ready-to-Use Therapeutic Food (RUTF) for Severe AcuteMalnutrition (SAM) and an Enteral Formula targeting the long-termeffects of COVID-19. AREV has identified a significant opportunityto fill the unmet global need for next generation products.
3) MedicineMerchant™ - The Company has invested in thedevelopment of a technology platform called Medicine Merchant.Developed from a database from a well-known high traffic cannabis seedsite, the platform is designed as the next generation technology insupport of the global cannabis industry. The enterprise system hasbeen extended to be scalable and can be skinned to serve a multitudeof commercial products and telemedicine. Dispensaries and Pharmaciescan embed their branded store on Medicine Merchant. The benefit to thedispensary is a cost savings from not having to build, maintain andmarket a website. Users will receive exposure to their physical storevia the high traffic to their virtual store embedded in MedicineMerchant. Traffic is generated by the Arev UX and Marketing Team.
Select dispensaries, processors and brand manufacturerscan serve as distributors to fulfil the customer orders. Raw materialsuppliers can be matched to manufacturers and marketers of brandedconsumer goods.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Life Sciences GlobalCorp.
The Company is a fully integrated enterprise withcompetencies in: 1) extraction of compounds for consumption andtopical use. 2) Clinical Nutrition and 3) A technology platform calledMedicine Merchant. The Company produces ingredients and formulatesexclusive therapeutic interventions with plans to deliver innovationin clinical nutrition, proprietary supplements, topicals and rationaldrug design, based on science. The Company’s business modelleverages its core competency of extraction to produce ingredients andcompounds for its pipeline of products. The Company continues inthe product development and pre-commercialization stage.
AREV is dedicated to designing and deliveringinnovation in rational drug design, driven by presenting globalepidemiological characteristics of multiple challenges tointernational human and animal health. AREV is a member of bothBIOTECanada and The Biotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This press release containsforward-looking statements. The use of any of the words"anticipate", "continue", "estimate","expect", "may", "will","project", "should", "believe" andsimilar expressions are intended to identify forward-lookingstatements. Although the Company believes that the expectations andassumptions on which the forward-looking statements are based arereasonable, undue reliance should not be placed on the forward-lookingstatements because the Company can give no assurance that they willprove to be correct. Since forward-looking statements
address future events and conditions, by their verynature they involve inherent risks and uncertainties. These statementsspeak only as of the date of this press release. Actual results coulddiffer materially from those currently anticipated due to a number offactors and risks various risk factors discussed in theCompany’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.